**Core tip:** Current literature regarding the use of biological mesh reconstruction after pelvic exenteration and extralevator abdominoperineal excision is scarce. However, it does suggest that the use of biological mesh has a lower short-term perineal hernia rate, but is probably not superior to other approaches with regards to perineal wound complications.

INTRODUCTION
============

Pelvic exenteration (PE) and extralevator abdominoperineal excision (ELAPE) are mutilating operations, leaving a large perineal incision. ELAPE for low rectal cancer was introduced to decrease the rate of positive resection margins and specimen perforation occurring during conventional abdominoperineal resection (cAPR)\[[@B1],[@B2]\]. In a recent retrospective study, Stelzner et al\[[@B3]\] showed that the 5-year recurrence rate was 5.9% in the ELAPE group *vs* 18.2% in the cAPR group (*P* = 0.153). However, other units have not been able to reproduce such results\[[@B4]\], nor could they demonstrate a statistically significant superiority of ELAPE in terms of CRM positivity and bowel perforation. Furthermore, they reported comparable perineal complication rates for the two APR approaches.

Vivid discussions continue to fuel the debate regarding the pros and cons of ELAPE. Overall, it is well accepted that larger wounds are independent risk factors for perineal wound complications. The combination of neoadjuvant chemoradiotherapy and ELAPE almost doubles the rate of perineal wound complications (31% for ELAPE *vs* 18% for cAPR)\[[@B5]\]. While new techniques and approaches have attempted to reduce the size of the perineal incision (and therefore reduce the risk of wound complications)\[[@B6]\], optimal management of perineal defects is still under investigation. The options include primary closure, myocutaneous flaps, and mesh reconstruction, including the use of a biological mesh.

We aimed to evaluate the outcomes of perineal reconstruction with biological mesh following ELAPE and PE in our center and to review the current literature.

CURRENT STATUS
==============

Perineal wound complications are a major concern following PE and ELAPE leading to increased morbidity, longer hospital stay, and delayed chemotherapy. Different reconstruction methods are currently used in practice with the aim of reducing the rates of wound complications and avoiding perineal herniation.

Risk factors for major perineal wound complications following APR are well known: Preoperative radiotherapy, patients with anal cancer, flap reconstruction, tumor size, obesity, and diabetes\[[@B7]\]. Minor wound complications appear more commonly in patients with inflammatory bowel disease or anal cancer than in those with rectal cancer\[[@B8]\].

Most patients with locally advanced rectal cancer, recurrent rectal cancer, and recurrent or persistent squamous cell carcinoma receive neoadjuvant radiochemotherapy or radiotherapy alone\[[@B9],[@B10]\]. The poor healing ability of irradiated wounds has been attributed to local endarteritis and damaged fibroblasts\[[@B11]\]. It has been clearly demonstrated that preoperative radiotherapy increases the rate of major wound complications\[[@B5],[@B12]\]. For example, Aldulaymi et al\[[@B13]\] reported a significantly increased risk of major perineal wound complications in patients undergoing APR for rectal cancer with primary closure of the perineum (26% in non-irradiated *vs* 71% in irradiated patients). Chadwick et al\[[@B14]\] found that the risk of developing a wound complication was 10 times higher after previous irradiation. This substantial problem with wound healing calls for the need to consider alternative closure techniques of the perineum.

Different methods have been described ranging from direct/primary closure to mesh reconstruction, gluteal and rectus abdominis flaps or combinations of these techniques. Currently, there is no consensus on which is the most ideal technique\[[@B15]\]. The vertical rectus abdominis flap (VRAM) is indicated to bring non-irradiated tissue into the perineal defect\[[@B16]\]. After VRAM, perineal wound complications have been reported to range from 0% to 28%\[[@B17]-[@B20]\]. The use of laparoscopy for the abdominal part of the resection is almost impossible because of the donor site. In addition, in cases of PE (with a right sided urostomy and left sided end colostomy), VRAM is often contra-indicated. A potential solution is the use of a wet double-barreled colostomy\[[@B21]\].

Other myocutaneous flaps can potentially be used, such as the gracilis flap and the gluteus maximus flap, which have a perineal wound complication rate of 12%\[[@B22]\] and 10%\[[@B2]\] respectively. However, these flaps are typically smaller than the VRAM flap and unlikely to provide adequate cover of large defects.

In addition, authors argue that myocutaneous flaps carry significant risks of donor site morbidity, flap necrosis, prolonged operative time, and usually require co-ordination with plastic surgeons\[[@B2],[@B23],[@B24]\]. Mesh reconstruction is another technique, which has attracted a lot of interest in the last few years, especially with the adoption of ELAPE. Briefly, the biological mesh is sutured directly to the pelvic side wall (Figure [1](#F1){ref-type="fig"}, Figure [2](#F2){ref-type="fig"}, Figure [3](#F3){ref-type="fig"}). The size of the mesh is adapted to the size of the defect. A perineal drain is routinely left at the end of the procedure, in order to avoid a perineal collection.

![Perineal view before reconstruction in pelvic exenteration patient.](WJCO-8-249-g001){#F1}

![Abdominal view before reconstruction in pelvic exenteration patient.](WJCO-8-249-g002){#F2}

![Perineal view after reconstruction using a biological mesh.](WJCO-8-249-g003){#F3}

Both allogenic and xenogenic biological meshes are available for the reconstruction of the perineum. These types of meshes were initially used for abdominal wall reconstructions\[[@B25],[@B26]\]. The allogenic mesh is predominantly made of human acellular dermis (*e.g*., HADM^®^ Ruinuo, Qingyuanweiye Bio-Tissue Engineering Ltd, Beijing, China) as used by Han et al\[[@B27],[@B28]\]. The xenogenic mesh consists of bovine pericardium or porcine dermis and intestinal mucosa. Similar to Musters et al\[[@B29]\] in the BIOPEX-study, we used the Strattice^®^ mesh (LifeCell, Acelity Company, Branchburg, NJ) which is composed of non-reticulated porcine dermis. Jensen et al\[[@B30]\] and Christensen et al\[[@B24]\] used the Permacol^®^ mesh (Tissue Science Laboratories plc, Covington, GA, United States) derived from reticulated porcine dermis\[[@B24],[@B30]\]. Surgisis^®^ Biodesign™ (Cook Medical, Bloomington, IN, United States) created using porcine intestinal mucosa was used by Peacock et al\[[@B31]\] for their pelvic reconstruction.

Reconstruction using a mesh is relatively simpler and faster compared to flap reconstruction\[[@B24]\]. When considering cost, meshes are expensive, especially if biological. However, with a potentially shorter operative time and length of hospital stay, overall costs can be controlled and even reduced in comparison to VRAM-flaps\[[@B32]\]. Biological meshes also have the advantage of being absorbable and can be used in infected environments\[[@B33]\].

On the other hand, perineal mesh reconstruction is not without its risks. Internal hernias following mesh repair have been reported. Melich et al\[[@B34]\] described resecting ischemic small bowel loops incarcerated in a pelvic hernia along the mesh in three patients. Jensen et al\[[@B30]\] reported a hole in the biological mesh in a patient with an infected perineal wound, who subsequently required mesh removal. These reports clearly raise concerns and highlight the risk of small bowel incarceration and necrosis associated with the use of a perineal mesh.

Table [1](#T1){ref-type="table"} summarizes the largest studies focusing on the use of biological mesh for perineal reconstruction. Interestingly, only one mesh was removed\[[@B30]\]. The overall safety profile appears to be good.

###### 

Perineal reconstruction with biological mesh

  **Ref**.                              **Study type**          **Operation**   **No.of patients**   **Average** **age (median years)**   **Perineal complications (%)**                                                            **Surgical perineal debridement** **n**                                                  **Perineal hernias**   **Follow up**   **Comments**
  ------------------------------------- ----------------------- --------------- -------------------- ------------------------------------ ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ---------------------- --------------- -----------------------------------------------------------------------------
  Musters BIOPEX-study 2016\[[@B29]\]   RCT                     ELAPE           50                   65                                   37% overall perineal wound complications                                                  4% surgical drainage of perineal abscess, 6% percutaneous drainage of perineal abscess   13% at 1 yr            12 mo           
  Jensen et al\[[@B30]\], 2014          Cohort, prospective     ELAPE           53                   NR                                   21% perineal fistula, 7.5% superficial perineal abscess, 7.5% deep perineal abscess       5 (9%) fistulectomy, 8 (15%) surgical debridements                                       5.60%                  Median 36 mo    1 mesh removed (infection), 1 mesh failure (hole) replacement of a new mesh
  Christensen et al\[[@B24]\], 2011     Cohort, retrospective   ELAPE           24                   69.7                                 17%, with one fistula after 3 mo                                                          0                                                                                        0                      Median 1.7 yr   \-
  Han et al\[[@B28]\], 2010             Cohort, retrospective   ELAPE           12                   68                                   16% infection, 8% seroma                                                                  0                                                                                        NR                     Median 8 mo     \-
  Han et al\[[@B27]\], 2012             Derived from RCT        ELAPE           32                   68                                   11.4% wound infections 11% seroma                                                         NR                                                                                       14%                    NR              \-
  Peacock et al\[[@B31]\], 2014         Cohort, prospective     ELAPE           34                   62                                   32% overall; 9% superficial wound infections, 14% perineal fistula; 9% perineal abscess   3 (9%) surgical debridement/VAC therapy                                                  0                      Median 21 mo    \-
  Schiltz present study                 Cohort, retrospective   ELAPE + PE      11                   63                                   Overall 27% wound infections with 1 superficial                                           2 (18%) surgical debridement                                                             0                      Mean 18 mo      \-

NR: Not reported; ELAPE: Extralevator abdominoperineal excision; PE: Pelvic exenteration.

Perineal wound complications
----------------------------

The clinical consequences of perineal wound complications are wide and range from a simple redness of the skin to a persistent perineal fistula, and perineal sepsis. Perineal wound complications are often subdivided into two subgroups: Early and delayed wound dehiscence. The delayed (\> 4 wk) perineal healing can occur in approximately 25% of cases. Importantly, up to 50% of these cases will develop long-term and persistent perineal symptoms such as pain, chronic sinus, sitting disability or tension between buttocks. All of which can seriously impact the patient's quality of life. Delayed perineal healing may therefore be a risk factor for persistent symptoms providing yet another reason why surgeons must strive to identify the best repair method possible\[[@B35],[@B36]\].

Primary closure leads to perineal wound complications in 18%-34%\[[@B27],[@B29],[@B37]\]. Moreover, one third of patients after PE will develop perineal wound dehiscence\[[@B38]\]. As a corollary, persistent presacral sinus was found in 10% of the patients following APR\[[@B39]\].

As mentioned in Table [1](#T1){ref-type="table"}, 17%-37% of patients with biological mesh presented some degree of perineal wound dehiscence/infection. A Danish retrospective study reported that 15% of patients with biological mesh had a surgical re-intervention for perineal infection. In addition, 21% of the patients had a perineal fistula with 9% requiring surgical excision\[[@B30]\]. Similarly, Peacock et al\[[@B31]\] reported an overall perineal wound complication rate of 32%. Vacuum assisted wound therapy and surgical debridement were needed in up to 9% of cases.

Christensen et al\[[@B24]\] compared gluteal flap reconstruction with biological mesh repair. Seventeen percent of patients in the mesh group had a wound infection compared to 6% in the flap group (*P* = 0.26). At 3 mo, all wounds healed with one persistent sinus in each group\[[@B24]\].

Han et al\[[@B28]\] found similar results and subsequently conducted a randomized controlled trial evaluating ELAPE *vs* cAPR. Interestingly, in the ELAPE group, patients had biological mesh reconstruction. Overall, the perineal wound infection rate (11.4%) after ELAPE was lower than in the cAPR group where 18.8% of patients developed a perineal complication. However, seromas were more frequent in the mesh group (11.4% *vs* 0%)\[[@B27]\]. Seroma formation can be problematic, pushing most of the authors to recommend the routine use of a perineal drain.

Adding to the present literature, we conducted a retrospective study of our local data. From January 2012 to December 2015, all patients undergoing ELAPE or PE with biological mesh reconstruction were analyzed. Eleven patients were found; all of whom had preoperative radiochemotherapy. Overall, perineal complications were found in 3 (27%) of the patients. In 2 (18%) patients, perineal abscesses were surgically drained and treated with a vacuum assisted wound closure system. One superficial wound infection was treated conservatively. No meshes were removed.

The relatively poor quality of the available studies in the literature remains an issue. These are mainly retrospective or simple cohort studies designed to analyze oncological outcomes. Very few of them focus specifically on perineal complications. Additionally, the severity and grading system of wound complications can differ between reports, and thus it is difficult to draw definitive conclusions.

The only multicenter randomized controlled trial focusing on perineal reconstruction using biological mesh after ELAPE, the BIOPEX study\[[@B29]\], was recently published. Patients were randomized into two groups, one with perineal mesh reconstruction and the other with primary closure only (control group). Regular blinded wound follow-up, using the Southampton wound healing score, did not show a significant difference between the two groups at 30 d. In the control group, 34% of perineal wound complications occurred *vs* 37% in the mesh group (*P* = 0.7177). At 12-mo follow-up, the healing rates did not differ between groups (52% *vs* 54%). Omentoplasty or use of perineal drains did not affect the results in this study\[[@B29]\].

In summary, current evidence suggests that biological mesh reconstruction does not appear to reduce the risk of perineal wound complications. Results are similar between primary closure, flap and biological mesh.

Perineal hernia
---------------

The incidence of perineal hernia after APR ranges from 0.6% to 27% in the literature\[[@B5],[@B29],[@B40]\], occurring on average 8 to 22 mo after surgery\[[@B41],[@B42]\] (Table [1](#T1){ref-type="table"}). Such a wide range can partly be explained by the definition of a perineal hernia itself. Indeed, a clinical hernia is quite different from an asymptomatic radiologically identified perineal hernia. Smoking and chemoradiotherapy are well reported risk factors\[[@B42]\].

Given that recurrence rates following perineal hernia repair are high (up to 37%), prevention is certainly the best strategy\[[@B15]\]. Perineal hernia occurs significantly less often after biological mesh reconstruction (0%) than following gluteal flap surgery (21%) (*P* \< 0.01)\[[@B24]\]. Thus suggesting that biological mesh repair can be a good option in order to avoid herniation.

The BIOPEX-study showed that 13% of perineal hernias (diagnosed on CT scan) occurred after biological mesh repair *vs* 27% in the primary closure group at one-year follow-up (*P* = 0.036)\[[@B29]\]. The hernias occurred nearer the end of the 12-mo follow-up in the mesh group. The long-term follow-up results are still pending. Interestingly, this delay in the hernia presentation is also described in patients without mesh reconstruction. However, this seems to occur after a median of 8 mo\[[@B41]\]. A possible explanation is that perineal hernias occur later in the mesh group due to the slower degradation of the biological mesh\[[@B43]\].

In our own data, no perineal hernia was found, neither clinically or radiologically, even after a mean follow-up of 18 mo.

Overall, biological mesh seems to protect, at least in early follow up, from the occurrence of perineal hernias in comparison to flap reconstruction or primary closure.

CONCLUSION
==========

Perineal reconstruction following ELAPE, APE or PE remains a major problem and challenge. No ideal solution currently exists but various approaches have been attempted with more or less success. Primary closure remains the most frequent technique, carrying a significant risk of perineal hernia formation. On the other hand, the use of flap or mesh reconstruction could help reduce the risk of herniation. Biological mesh appears to be a valid option, at least in terms of hernia prevention, which can be reduced by up to 50%.

Yet, the role of mesh reconstruction in reducing wound infections is less clear. Whilst perineal infection is frequent in irradiated patients, the use of biological mesh seems logical, even if the evidence is scarce to draw definitive recommendations. On the other hand, perineal wound infection remains frequent and a perineal drain should be routinely used.
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